Cited by 286Breast Cancer Treatment StudiesCancer survivorship and careMenopause: Health Impacts and Treatments

The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.

Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy

Open access

Cella, David, Fallowfield, Lesley J.·2008·Breast Cancer Research and Treatment

Open this paper in CoChat — free account

Abstract

In postmenopausal women with hormone receptor-positive early-stage breast cancer, the use of aromatase inhibitors (AIs) to suppress estrogen is associated with improved clinical outcomes compared with tamoxifen therapy. Women receiving such endocrine therapy may experience treatment-related side effects that negatively affect health-related quality of life (QoL) and adherence to therapy. In published clinical trials and in clinical practice, adverse events (AEs) constitute the main reason for nonadherence to endocrine treatment. Serious AEs are sometimes resolved by switching to a different agent, whereas other side effects can often be managed to allow patients to remain on therapy without sacrificing QoL. Across all adjuvant endocrine trials, regardless of the treatment received, vasomotor symptoms such as hot flashes are the most common side effects. Other frequently reported side effects, such as vaginal discharge, vaginal dryness, dyspareunia, and arthralgia, vary in prevalence between tamoxifen and AIs. Here we provide an overview of reported AEs of adjuvant endocrine therapy, focusing on those that are amenable to pharmacologic or nonpharmacologic management without treatment discontinuation. Also highlighted are specific management strategies that may improve patient QoL and thereby optimize adherence to therapy, which in turn might improve patient outcomes.

Integrity signals

Registry

Crossref · 10.1007/s10549-007-9548-1

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 retracted

RETRACTED: Drug-induced lupus erythematosus
Sarzi‐Puttini, P., Atzeni, F., Sarzi‐Puttini, P., Atzeni, F., CAPSONI, F., Sarzi‐Puttini, P., Atzeni, F., CAPSONI, F., Lubrano, E., Sarzi‐Puttini, P., et al. (2005) · Autoimmunity · doi:10.1080/08916930500285857 · Cited by 125
Retracted
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
Howell, A., Cuzick, J. M., Baum, M., Buzdar, A. U., Dowsett, M., Forbes, J., Hoctin-Boes, G., Houghton, J., Locker, G. Y., & Tobias, J. S. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17666-6 · Cited by 2,284 · cited 1×
“Conversely, the systemic estrogen deprivation that results from AI therapy in postmenopausal women can result in bone resorption and osteoporosis, with higher fracture rates [2, 4, 7].”
Background
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
Baum, M., Budzar, A. U., Cuzick, J. M., Forbes, J., Houghton, J., Klijn, J. G. M., & Sahmoud, T. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09088-8 · Cited by 1,958
A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
Self-citation
A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer
The Breast International Group (BIG) 1-98 Collaborative Group (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052258 · Cited by 1,584
Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M. M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji250 · Cited by 1,116 · cited 3×
“005), suggesting inhibition of endometrial proliferation by the AI [7].”
BackgroundMethodInfluential
American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004
Winer, E. P., Hudis, C. A., Burstein, H. J., Wolff, A. C., Pritchard, K. I., Ingle, J. N., Chlebowski, R. T., Gelber, R. D., Edge, S. B., Gralow, J. R., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.121 · Cited by 1,026
Transdermal testosterone treatment in women with impaired sexual function after oophorectomy.
Shifren, J. L., Braunstein, G. D., Simon, J. A., Casson, P. R., Buster, J. E., Redmond, G. P., Burki, R. E., Ginsburg, E. S., Rosen, R. C., Leiblum, S. R., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009073431002 · Cited by 954 · cited 1×
“Loss of libido Better patient/physician communication Transdermal testosterone Shifren et al. [ 66 ]”
Background
CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment
Jin, Y., Desta, Z., Stearns, V., Ward, B. A., Ho, H., Lee, K.-H., Skaar, T. C., Storniolo, A. M., Li, L., Araba, A., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji005 · Cited by 951

Show all 83 references

Research works printed but not linked: 4

Taylor M, Rastelli A, Civitelli R et al (2004) Incidence of 25-OH vitamin D deficiency in patients with a history of breast cancer who have musculoskeletal symptomatology. Abstract presented at the 27th Annual San Antonio Breast Cancer Symposium; December 8–11, 2004; San Antonio, TX
Thompson JN, Napoli N, Civitelli R et al (2006) Effects of dietary calcium vs. calcium supplements on estrogen metabolism and bone density. Osteoporos Int 17:S205 (abstract P696MO)
Plourde P, Locker G, Hoctin-Boes G et al (2005) Arthralgia in postmenopausal breast cancer patients on adjuvant endocrine therapy: a risk-benefit analysis. Poster presented at: 7th Annual Lynn Sage Breast Cancer Symposium; October 6–9 2005; Chicago, Illinois
Mok K, Mireskandari S, Juraskova I et al (2006) OVER (Olive oil Vaginal Exercises and Replens) Come. Psycho-Oncology 15:S332 (abstract 778)

Sorted by citations

Items 101–200 of 286

Sleep difficulty mediates effects of vasomotor symptoms on mood in younger breast cancer survivors
Vincent, A. J., Ranasinha, S., Sayakhot, P., Mansfield, D. R., & Teede, H. J. (2014) · Climacteric · doi:10.3109/13697137.2014.900745 · Cited by 31
A systematic review of eHealth technologies for breast cancer supportive care
Gyawali, B., Bowman, M., Sharpe, I., Jalink, M., Srivastava, S., & Wijeratne, D. T. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102519 · Cited by 28
Patient-provider communication and hormonal therapy side effects in breast cancer survivors
Lin, J. J., Chao, J., Bickell, N. A., & Wisnivesky, J. P. (2016) · Women & Health · doi:10.1080/03630242.2016.1235071 · Cited by 28
“Several other studies also demonstrated that patients who experienced side effects were more likely to stop taking HT (Buzdar, Howell et al. 2006; Lash, Fox et al. 2006; Cella and Fallowfield 2008).”
Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole
Singh, S., Cuzick, J. M., Mesher, D., Richmond, B., & Howell, A. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1911-6 · Cited by 28
“Arthralgia is considered a class effect of AIs, with an incidence 2–8% higher in patients treated with AIs than among those treated with tamoxifen in blinded controlled randomized trials [18].”
Background
Partner status moderates the relationships between sexual problems and self-efficacy for managing sexual problems and psychosocial quality-of-life for postmenopausal breast cancer survivors taking adjuvant endocrine therapy
Dorfman, C. S., Arthur, S. S., Kimmick, G. G., Westbrook, K. E., Marcom, P. K., Corbett, C. M., Edmond, S. N., & Shelby, R. A. (2019) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001337 · Cited by 25
A Self-Report Instrument That Describes Urogenital Atrophy Symptoms in Breast Cancer Survivors
Lester, J., Bernhard, L. A., & Ryan‐Wenger, N. A. (2010) · Western Journal of Nursing Research · doi:10.1177/0193945910391483 · Cited by 26
“…to genital and/or vaginal pain, burning with urination after SA, worry about pregnancy, happiness with sex life, and ability to talk with partner (Broeckel, Thors, Jacobsen, Small, & Cox, 2002; Cella & Fallowfield, 2008; Ganz et al., 1999; Huber, Ramnarace, & McCaffrey, 2006; Speer et al., 2005).”
Background
The adverse effects of trastuzumab-containing regimes as a therapy in breast cancer: A piggy-back systematic review and meta-analysis
Jackson, C., Finikarides, L., & Freeman, A. L. J. (2022) · PLoS ONE · doi:10.1371/journal.pone.0275321 · Cited by 25
Sexual dysfunctions in breast cancer patients: evidence in context
Vizza, R., Capomolla, E. M., Tosetto, L., Corrado, G., Bruno, V., Chiofalo, B., Lisa, F. S. D., Filomeno, L., Pizzuti, L., Krasniqi, E., et al. (2023) · Sexual Medicine Reviews · doi:10.1093/sxmrev/qead006 · Cited by 24
A review of the use of exemestane in early breast cancer.
Robinson, A. G. (2009) · PubMed Central · Cited by 24
Race and Patient-reported Symptoms in Adherence to Adjuvant Endocrine Therapy: A Report from the Women's Hormonal Initiation and Persistence Study
Sheppard, V. B., Sutton, A. L., Hurtado‐de‐Mendoza, A., He, J., Dahman, B. A., Edmonds, M. C., Hackney, M. H., & Tadesse, M. G. (2021) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-20-0604 · Cited by 25
Predicting nonadherence to adjuvant endocrine therapy in women with early stage breast cancer
Corter, A. L., Broom, R. J., Porter, D. J. T., Harvey, V. J., & Findlay, M. P. N. (2018) · Psycho-Oncology · doi:10.1002/pon.4771 · Cited by 24
Endocrine Therapy With or Without CDK4/6 Inhibitors in Women With Hormone-receptor Positive Breast Cancer: What do we Know About the Effects on Cognition?
Kjoe, P. R. L. M., van der Wall, E., & Schagen, S. B. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.08.002 · Cited by 23
Comparison of physical interventions, behavioral interventions, natural health products, and pharmacologics to manage hot flashes in patients with breast or prostate cancer: protocol for a systematic review incorporating network meta-analyses
Hutton, B., Yazdi, F., Bordeleau, L. J., Morgan, S. C., Cameron, C. G., Kanji, S., Fergusson, D. A., Tricco, A. C., Straus, S. E., Skidmore, B., et al. (2015) · Systematic Reviews · doi:10.1186/s13643-015-0099-y · Cited by 22
“As endocrine manipulation is the mainstay of treatment for both diseases, it is not surprising that hot flashes are a troublesome side effect in two of every three patients receiving endocrine therapy [3].”
Background
Management of menopause in women with breast cancer
Vincent, A. J. (2014) · Climacteric · doi:10.3109/13697137.2014.996749 · Cited by 22
Geographic disparities in adherence to adjuvant endocrine therapy in Appalachian women with breast cancer
Tan, X., Camacho, F., Marshall, V. D., Donohoe, J., Anderson, R. T., & Balkrishnan, R. (2016) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2016.08.004 · Cited by 22
British Menopause Society consensus statement on the management of estrogen deficiency symptoms, arthralgia and menopause diagnosis in women treated for early breast cancer
Marsden, J., Marsh, M., Rigg, A. S., & on behalf of The British Menopause Society (2019) · Post Reproductive Health · doi:10.1177/2053369118824920 · Cited by 22
“(I) If a patient develops vasomotor symptoms an indication of how troublesome they are likely to be can be estimated after about three to six months from the start of treatment as if vasomotor symptoms will reduce with time they usually do so at around three months.(16) (II) A variety of non-hormonal methods of treatm…”
Influential
Breast Cancer Survivors and Hot Flashes: The Search for Nonhormonal Treatments
Avis, N. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.2170 · Cited by 22
Symptoms, unmet need, and quality of life among recent breast cancer survivors
Palmer, S., DeMichele, A. M., Schapira, M. M., Glanz, K., Blauch, A. N., Pucci, D. A., & Jacobs, L. A. (2016) · The Journal of Community and Supportive Oncology · doi:10.12788/jcso.0236 · Cited by 22
Strategies to self-manage side-effects of adjuvant endocrine therapy among breast cancer survivors: an umbrella review of empirical evidence and clinical guidelines
Hall, L., King, N. V., Graham, C. D., Green, S. M. C., Barber, A., Neal, R. D., Foy, R., Clark, J., Lloyd, K. E., & Smith, S. G. (2021) · Journal of Cancer Survivorship · doi:10.1007/s11764-021-01114-7 · Cited by 22
Vaginal Estrogen Therapy for Patients with Breast Cancer
Mögele, M., Buchholz, S., Seitz, S., Lattrich, C., & Ortmann, O. (2013) · Geburtshilfe und Frauenheilkunde · doi:10.1055/s-0033-1350876 · Cited by 20
Adjuvant therapy use among Appalachian breast cancer survivors
Tan, X., Marshall, V. D., Anderson, R. T., Donohoe, J., Camacho, F., & Balkrishnan, R. (2015) · Medicine · doi:10.1097/md.0000000000001071 · Cited by 20
“As per clinical recommendations for managing AET-associated side effects, 17–19 we created dummy variables indicating whether or not patients used antidepressants (fluoxetine, paroxetine, venlafaxine, citalopram, gabapentin), bisphosphonates (zoledronic acid, alendronate, risedronate), and pain…”
Method
Treatment interruption and discontinuation of hormonal therapy in hormone receptor-positive breast cancer patients
Mao, D., Hachem, H., Chang, H., Dima, D., Dower, J., Wismer, M., Erban, J. K., Freund, K. M., & Parsons, S. K. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05892-z · Cited by 20
Refining and optimising a behavioural intervention to support endocrine therapy adherence (ROSETA) in UK women with breast cancer: Protocol for a pilot fractional factorial trial
Smith, S. G., Green, S. M. C., Ellison, R., Foy, R., Graham, C. D., Mason, E., French, D. P., Hall, L. H., Wilkes, H., McNaught, E., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-069971 · Cited by 20
Association of sarcopenia with endocrine therapy toxicity in patients with early breast cancer
Aleixo, G. F. P., Valente, S. A., Wei, W., & Moore, H. C. F. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06741-x · Cited by 21
“Common side effects of endocrine therapy include musculoskeletal pain (arthralgias), hot flashes, and fatigue; in addition, endocrine treatments have been associated with bone density loss and cardiovascular events [4, 5].”
Background
Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance)
Bluethmann, S. M., Alfano, C. M., Clapp, J. D., Luta, G., Small, B. J., Hurria, A., Cohen, H. J., Sugarman, S. M., Muss, H. B., Isaacs, C. J., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4353-y · Cited by 19
“Next, the various classes of hormonal therapy may have different side effect profiles, including adverse cognitive effects [4, 40, 49].”
Topical treatment of vaginal dryness with a non-hormonal cream in women undergoing breast cancer treatment - An open prospective multicenter study
Chatsiproios, D., Schmidts-Winkler, I. M., König, L., Masur, C., & Abels, C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210967 · Cited by 19
“VVD symptoms develop after starting treatment in a high percentage of breast cancer patients [7], which constitute one of the main reasons for discontinuation of and non-adherence to endocrine treatment [8, 9], accounting for a decreased survival [10].”
Background
Addressing sexual concerns of female breast cancer survivors and partners: a qualitative study of survivors, partners, and oncology providers about Internet intervention preferences
Shaffer, K. M., Kennedy, E. D., Glazer, J. V., Clayton, A. H., Cohn, W. F., Millard, T. A., Ritterband, L. M., & Showalter, S. L. (2021) · Supportive Care in Cancer · doi:10.1007/s00520-021-06302-w · Cited by 19
Bupropion for Control of Hot Flashes in Breast Cancer Survivors: A Prospective, Double-Blind, Randomized, Crossover, Pilot Phase II Trial
Nuñez, G. R., Pinczowski, H., Zanellato, R. M., Tateyama, L., Schindler, F., Fonseca, F. L. A., & del Giglio, A. (2012) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2012.06.011 · Cited by 19
“In fact, the rate of noncompliance to endocrine treatment varies from 25% to 55%, with adverse effects rated as the primary reason.(9) Interestingly, one study reported poor compliance in more than 50% of patients within 180 days of using an antiestrogen medication.”
Background
A review of the use of exemestane in early breast cancer
Robinson, A. G. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3422 · Cited by 29
“36 If symptoms persist, one can decide based on the baseline risk of death from cancer in the patient whether continuing with exemestane and adding anti-inﬂ ammatory medicines or acetaminophen is warranted, or whether switching to different aromatase inhibitors and possibly back to tamoxifen would…”
Testing a behavioral intervention to improve adherence to adjuvant endocrine therapy (AET)
Shelby, R. A., Dorfman, C. S., Bosworth, H. B., Keefe, F., Sutton, L., Owen, L., Corsino, L., Erkanli, A., Reed, S. D., Arthur, S. S., et al. (2019) · Contemporary Clinical Trials · doi:10.1016/j.cct.2018.11.010 · Cited by 18
Vaginal Laser Treatment for the Genitourinary Syndrome of Menopause in Breast Cancer Survivors: A Narrative Review
Okui, N. (2023) · Cureus · doi:10.7759/cureus.45495 · Cited by 18
“Furthermore, tamoxifen is associated with an increased likelihood of vaginal discharge [27,38].”
Background
Acceptance and Commitment Therapy to support medication decision-making and quality of life in women with breast cancer: protocol for a pilot randomised controlled trial
Smith, S. G., Ellison, R., Hall, L., Clark, J., Hartley, S., Mason, E., Metherell, J., Olivier, C., Napp, V., Naik, J., et al. (2022) · Pilot and Feasibility Studies · doi:10.1186/s40814-022-00985-6 · Cited by 17
“Common side-effects include hot ushes and night sweats, which affect up to 85% of women treated for breast cancer (16), and can compromise quality of life (17, 18).”
Background
Treatment and patient related quality of life issues in elderly and very elderly breast cancer patients
Denizli, B. (2020) · Translational Cancer Research · doi:10.21037/tcr.2019.07.08 · Cited by 17
“In case of poor management, they may even cause discontinuation of treatment thus worsening the outcome (44-46).”
Background
Tamoxifen related side effects and their impact on breast cancer incidence: A retrospective analysis of the randomised IBIS-I trial
Hale, M. J., Howell, A., Dowsett, M., Cuzick, J. M., & Šestak, I. (2020) · The Breast · doi:10.1016/j.breast.2020.10.015 · Cited by 17
“This suggests two different mechanisms between tamoxifen and AIs in the vaginal tract [21,22].”
Background
Health-related quality of life in breast cancer patients in Asia: A meta-analysis and systematic review
Chen, X., Wu, C., Bai, D., Gao, J. X., Hou, C., Chen, T., Zhang, L., & Luo, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.954179 · Cited by 16
“The decline of the sexual functioning of BC patients could be caused by various treatments, such as the commonly used drugs tamoxifen and aromatase inhibitors in adjuvant endocrine therapy, whose side effects of vaginal dryness and dyspareunia are often reported in reviews (68).”
Background
Emerging Use of Vaginal Laser to Treat Genitourinary Syndrome of Menopause for Breast Cancer Survivors: A Review
Jugulytė, N., Žukienė, G., & Bartkevičienė, D. (2023) · Medicina · doi:10.3390/medicina59010132 · Cited by 16
“With regard to endocrine therapy, several studies have demonstrated that AIs-treated patients report GSM symptoms more often than tamoxifen-treated women [48–50,60], but vaginal discharge is mostly attributed to tamoxifen [49,60].”
Background
An Update on Tamoxifen and the Chemo-Preventive Potential of Vitamin E in Breast Cancer Management
Khallouki, F., Hajji, L., Saber, S., Bouddine, T., Edderkaoui, M., Bourhia, M., Mir, N., Lim, A., Midaoui, A. E., Giesy, J. P., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13050754 · Cited by 18
Dietary modification for women after breast cancer treatment: a narrative review
Tramm, R., McCarthy, A. L., & Yates, P. M. (2011) · European Journal of Cancer Care · doi:10.1111/j.1365-2354.2011.01238.x · Cited by 19
“Their memory can also be significantly affected by cytotoxic treatments and treatment-induced menopause during and after treatment (Cella & Fallowfield 2008).”
Background
Breast Cancer in Young Women and Its Impact on Reproductive Function
Mir, R., & Singh, V. P. P. (2009) · Apollo Medicine · doi:10.1016/s0976-0016(11)60528-0 · Cited by 16
The lived experience of patients with breast cancer on adjuvant endocrine therapy: side effects and coping strategies during the first year of medication initiation
Gomaa, S., López, A., Slamon, R., Smith, R. M., Telushi, E., Lapitan, E., Nightingale, G., Miller, S., & Wen, K. (2023) · Supportive Care in Cancer · doi:10.1007/s00520-023-08170-y · Cited by 15
Antihormonal treatment associated musculoskeletal pain in women with breast cancer in the adjuvant setting
Seber, S., Solmaz, D., & Yetişyiğit, T. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s108968 · Cited by 16
“15 It can be hypothesized that younger patients will be more sensitive to the adverse effects of the acute reduction of sex hormones due to hormonal treatment, when compared to their older counterparts.”
Exercise Interventions for Survivors of Cancer Living in Rural or Remote Settings: A Scoping Review
Smith‐Turchyn, J., Gravesande, J., & Sabiston, C. M. (2020) · Rehabilitation Oncology · doi:10.1097/01.reo.0000000000000208 · Cited by 17
Symptom Clusters and Quality of Life in Patients With Breast Cancer Receiving Endocrine Therapy in China
Jing, F., Zhu, Z., Qiu, J., Tang, L., Xu, L., Xing, W., & Hu, Y. (2023) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2023.151443 · Cited by 14
Effects of non-pharmacological supportive care for hot flushes in breast cancer: a meta-analysis
Tao, W.-W., Tao, X.-M., & Song, C. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-017-3691-y · Cited by 15
Racial Differences in Depressive Symptoms and Self-Rated Health Among Breast Cancer Survivors on Aromatase Inhibitor Therapy
Calhoun, C., Helzlsouer, K. J., & Gallicchio, L. M. (2015) · Journal of Psychosocial Oncology · doi:10.1080/07347332.2015.1019661 · Cited by 14
Provider perspectives on patient-provider communication for adjuvant endocrine therapy symptom management
Turner, K. L., Samuel, C. A., Donovan, H. A., Beckjord, E. B., Cardy, A., Dew, M. A., & Londen, G. J. V. (2016) · Supportive Care in Cancer · doi:10.1007/s00520-016-3491-9 · Cited by 15
Effects of Menopausal Symptoms and Depression on the Quality of Life of Premenopausal Women With Breast Cancer in Korea
Han, J. A., Choi, S. Y., & Lee, S. (2018) · Journal of Transcultural Nursing · doi:10.1177/1043659618771475 · Cited by 14
Bridging the gap: incorporating exercise evidence into clinical practice in breast cancer care
Smith‐Turchyn, J., Richardson, J. A., Tozer, R. G., McNeely, M. L., & Thabane, L. (2019) · Supportive Care in Cancer · doi:10.1007/s00520-019-04897-9 · Cited by 14
Evaluation of estrogenic potential of Shu-Gan-Liang-Xue Decoction by dual-luciferase reporter based bioluminescent measurements in vitro
Zhang, Y., & Li, P. (2009) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2009.08.016 · Cited by 14
Quantitative comparison of drug efficacy in treating hot flashes in patients with breast cancer
Li, T., Yang, J., Lv, Y., Yin, F., Xu, L., Liu, H., Zheng, Q., & Li, L. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-5029-y · Cited by 14
Quality of life in elderly breast cancer patients with localized disease receiving endocrine treatment: a prospective study
Arrarás, J. I., Illarramendi, J. J., Manterola, A., Asín, G., Salgado, E., Arrondo, P., Dominguez, M. A., Arrazubi, V., Martinez, E., Viúdez, A., et al. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02048-4 · Cited by 13
Physical activity and health-related quality of life among postmenopausal women with breast cancer treated with aromatase inhibitors
Dibble, K. E., Bellizzi, K. M., Taxel, P., Pescatello, L. S., Siembida, E. J., Schifano, E. D., Guarneri, S., & Tannenbaum, S. H. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05741-1 · Cited by 13
Understanding how to reach the hard to reach in cancer rehabilitation
(2020) · Global Journal of Nursing · doi:10.28933/gjn-2020-10-3005 · Cited by 15
Feasibility of a Supervised Virtual Exercise Program for Women on Hormone Therapy for Breast Cancer
Myers, S. A., Weller, S., Schwartz, S., Patten, C. L. V., LeVasseur, N., Faulkner, G., & Campbell, K. L. (2022) · Translational Journal of the American College of Sports Medicine · doi:10.1249/tjx.0000000000000213 · Cited by 13
“Adverse treatment side effects are common and can include vasomotor symptoms, arthralgias, weight gain, and bone loss, which negatively affect quality of life (QoL) (4,5).”
Background
A Pilot Investigation of Guided Self-Hypnosis in the Treatment of Hot Flashes Among Postmenopausal Women
Elkins, G., Johnson, A., Fisher, W., Sliwinski, J., & Keith, T. (2013) · International Journal of Clinical and Experimental Hypnosis · doi:10.1080/00207144.2013.784112 · Cited by 13
“In fact, recent sampling suggests that anywhere from 25% to 55% of women refuse to continue traditional treatments due to adverse events (Cella & Fallowfield, 2008).”
Background
The use of Nolvadex in the treatment of generic Tamoxifen-associated small joint arthralgia
Blencowe, N., Reichl, C., Gahir, J., & Paterson, I. (2010) · The Breast · doi:10.1016/j.breast.2010.02.004 · Cited by 13
Racial and geographic disparities in adherence and discontinuation to adjuvant endocrine therapy in Texas Medicaid-insured patients with breast cancer
Farias, A. J., Wu, W.-H., & Du, X. L. (2018) · Medical Oncology · doi:10.1007/s12032-018-1168-6 · Cited by 13
Factors analysis on the use of key quality indicators for narrowing the gap of quality of care of breast cancer
Wang, C., Li, X., Su, S., Wang, X., Li, J., Bao, X., & Liu, M. (2019) · BMC Cancer · doi:10.1186/s12885-019-6334-5 · Cited by 12
Population-based estimates of overtreatment with adjuvant systemic therapy in early breast cancer patients with data from the Netherlands and the USA
Ragusi, M. A. A., van der Velden, B. H. M., van Maaren, M. C., van der Wall, E., van Gils, C. H., Pijnappel, R. M., Gilhuijs, K. G. A., & Elias, S. G. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06550-2 · Cited by 13
Hot flashes
Kadakia, K. C., Loprinzi, C. L., & Barton, D. L. (2012) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3182578d31 · Cited by 12
Psychologische Optimierung von Erwartungen zur Prävention von Nocebo-Nebenwirkungen bei Brustkrebs - 2 Fallberichte
von Blanckenburg, P., Schuricht, F., Heisig, S. R., Mora, M. C. S., Rehahn-Sommer, S., Albert, U., Rief, W., & Nestoriuc, Y. (2015) · Verhaltenstherapie · doi:10.1159/000377711 · Cited by 12
Menopausal hormone therapy for breast cancer patients: what is the current evidence?
Glynne, S., Simon, J. A., Branson, A., Payne, S. J., Newson, L. R., Manyonda, I., Cleator, S. J., Douek, M., USISKIN, S. I., Tobias, J. S., et al. (2025) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002627 · Cited by 12
“18 However, in chemoprevention randomised trials, symptom prevalence in women assigned to placebo was also high, suggesting that symptoms may not always be treatment-induced side effects.”
Symptom Profiles and Related Factors Among Breast Cancer Patients Undergoing Endocrine Therapy
Jing, F., Zhu, Z., Qiu, J., Tang, L., Xu, L., & Xing, W. (2022) · Cancer Nursing · doi:10.1097/ncc.0000000000001125 · Cited by 11
CO2 Laser Therapy for Genitourinary Syndrome of Menopause in Women with Breast Cancer: A Randomized, Sham-Controlled Trial
Jaber, S., Levin, G., Ram-Weiner, M., & Lev‐Sagie, A. (2025) · Cancers · doi:10.3390/cancers17071241 · Cited by 11
“Non-hormonal vaginal moisturizers and lubricants often prove unsatisfactory, especially with severe symptoms [6,7].”
Adjuvant Endocrine Therapy for the Surgeon: Options, Side Effects, and their Management
Connor, C. S., & Attai, D. J. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3177-1 · Cited by 11
“Most symptoms are mild to moderate, improve without specific intervention, and resolve after therapy is completed.(20,31) Switching to a different AI may help.”
Influential
Effects of Prophylactic Administration of Granulocyte Colony-Stimulating Factor on Peripheral Leukocyte and Neutrophil Counts Levels After Chemotherapy in Patients With Early-Stage Breast Cancer: A Retrospective Cohort Study
Tian, W., Wang, Y., Zhou, Y., Yao, Y., & Deng, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.777602 · Cited by 11
“Early-stage triple-negative breast cancer (TNBC) patients rarely undergo further treatment after adjuvant chemotherapy, but ESBC patients with Her-2 and HR-positive still need endocrine (40) and targeted (41) therapy after chemotherapy, which also affects the recovery of ANCs and contribute to common side effects, inc…”
Background
The Importance of Nonpharmacogenetic Factors in Endocrine Therapy
McCowan, C., & Thompson, A. M. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.29 · Cited by 11
Providers’ perspectives on adherence to hormonal therapy in breast cancer survivors. Is there a role for the digital health feedback system?
Hurtado‐de‐Mendoza, A., Cabling, M. L., Dilawari, A. A., Turner, J. W., Fernández, N. C., Henderson, A., Zhu, Q., Gómez‐Trillos, S., & Sheppard, V. B. (2018) · Health and Technology · doi:10.1007/s12553-018-0267-x · Cited by 12
Endocrine Therapy–Related Symptoms and Quality of Life in Female Cancer Survivors in the Yale Fitness Intervention Trial
Park, S., Knobf, M. T., & Jeon, S. (2019) · Journal of Nursing Scholarship · doi:10.1111/jnu.12471 · Cited by 12
The effect of treatment and coping on the quality of life in breast cancer patients: a moderated mediation model
Gutiérrez, L., Furlong, L. V., Sánchez-Román, S., Berzal-Pérez, E., Castillejos, N. A., & Quiróz-Friedman, P. (2021) · Quality of Life Research · doi:10.1007/s11136-021-02885-3 · Cited by 10
“The use of tamoxifen or aromatase inhibitors is associated with an increase in long-term side effects such as musculoskeletal or gynaecological problems [44, 45].”
Background
The Experience of Patients with Endocrine Therapy for Breast Cancer: A Patient Journey Map Based on Qualitative Research
Yao, Y., He, T., & Tian, X. (2024) · Current Oncology · doi:10.3390/curroncol31100437 · Cited by 10
“Adjuvant endocrine therapy (AET) has been shown to significantly reduce mortality and recurrence risk among ER (+) patients [3,4]; however, it is often accompanied by side effects such as hot flashes and osteoporosis [5].”
Background
The British menopause society consensus statement on the management of estrogen deficiency symptoms, arthralgia and menopause diagnosis in women with treated for early breast cancer
Marsden, J. (2022) · Post Reproductive Health · doi:10.1177/20533691221122358 · Cited by 10
“In postmenopausal women both tamoxifen and aromatase inhibitors are associated with induction of vasomotor symptoms.(17) Symptoms usually persist for the duration of exposure but their severity may decrease over time.”
Background
A pilot study on aesthetic treatments performed by qualified aesthetic practitioners: efficacy on health-related quality of life in breast cancer patients
Oliveri, S., Faccio, F., Pizzoli, S. F. M., Monzani, D., Redaelli, C., Indino, M., & Pravettoni, G. (2019) · Quality of Life Research · doi:10.1007/s11136-019-02133-9 · Cited by 10
THRIVE intervention development: using participatory action research principles to guide a mHealth app-based intervention to improve oncology care
Anderson, J. N., Krukowski, R. A., Paladino, A. J., Graff, J. C., Schwartzberg, L. S., Curry, A. N., Vidal, G. A., Jones, T. N., Waters, T. M., & Graetz, I. (2020) · Journal of Hospital Management and Health Policy · doi:10.21037/jhmhp-20-103 · Cited by 12
“Women on AET frequently report negative symptoms, such as pain, fatigue, hot flashes, sexual dysfunction and mental health challenges, all of which can negatively impact quality of life during survivorship (6-8).”
Rationale and usability findings of an e-health intervention to improve oral anticancer adherence among breast cancer survivors: The My Journey mindfulness study
Yanez, B. R., Oswald, L. B., Denburg, A. N. V., Baik, S. H., Czech, K. A., Buitrago, D., Maletich, C., Wortman, K., Penedo, F. J., & Victorson, D. E. (2022) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2022.100898 · Cited by 10
Prevention of osteoporosis as a consequence of aromatase inhibitor therapy in postmenopausal women with early breast cancer: Rationale and design of a randomized controlled trial
Kilbreath, S. L., Refshauge, K. M., Beith, J. M., Ward, L. C., Sawkins, K., Paterson, R., Clifton‐Bligh, P., Sambrook, P. N., Simpson, J. M., & Nery, L. (2011) · Contemporary Clinical Trials · doi:10.1016/j.cct.2011.04.012 · Cited by 10
“The long-term use of tamoxifen, however, has been associated with side effects such as vaginal discharge and bleeding, cerebrovascular events, venous thromboembolic events and endometrial cancer [5,6].”
Background
Association between chronic pain and quality of life in long-term breast cancer survivors: a prospective analysis
Yin, M., Gu, K., Cai, H., & Shu, X. (2023) · Breast Cancer · doi:10.1007/s12282-023-01472-3 · Cited by 9
“Breast cancer patients experience a variety of physical and mental issues [16] ranging from increased risk of cardiovascular disease [17] to depression [18, 19] due to the side effects and stress of treatment; thus, quality of life shortly after diagnosis can be much lower than before diagnosis [20].”
Background
Exploring women's experiences with persistent pain and pain management following breast cancer treatment: A qualitative study
Smith, M. D., Manning, J., Nielsen, M., Hayes, S. C., Plinsinga, M. L., & Coppieters, M. W. (2023) · Frontiers in Pain Research · doi:10.3389/fpain.2023.1095377 · Cited by 9
“Persistent pain has also been identified as a cause of discontinuing or adjusting various specific breast cancer treatments like changes to aromatase inhibitors, and therefore potentially influences risk of recurrence, disease progression and mortality (15, 16).”
Background
Physical activity and breast cancer: Results of a focus group to devise novel exercise interventions for women with breast cancer
Smith‐Turchyn, J., Richardson, J. A., Tozer, R. G., Thabane, L., & McNeely, M. L. (2017) · Clinical Nursing Studies · doi:10.5430/cns.v6n2p39 · Cited by 9
The early discontinuation of adjuvant hormone therapy is associated with a poor prognosis in Japanese breast cancer patients
Taketani, K., Tokunaga, E., Yamashita, N., Tanaka, K., Akiyoshi, S., Okada, S., Ando, K., Kimura, Y., Saeki, H., Oki, E., et al. (2013) · Surgery Today · doi:10.1007/s00595-013-0762-7 · Cited by 10
“A consistent finding in the literature is that treatment side effects are strongly associated with adherence to or continuation with adjuvant therapy [29].”
Background
A Pilot Study of Website Information Regarding Aromatase Inhibitors: Dietary Supplement Interactions
McDermott, C. L., Hsieh, A. A., Sweet, E. S., Tippens, K. M., & McCune, J. S. (2011) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2010.0471 · Cited by 9
“Nonadherence rates range from 25% to 55% in patients with breast cancer, with nonadherence being primarily due to drug toxicity.(16,17) Common toxicities to the AIs include musculoskeletal”
Background
Patient experience of taking adjuvant endocrine therapy for breast cancer: a tough pill to swallow
Wen, K., Smith, R. F., Padmanabhan, A., & Goldstein, L. J. (2017) · Patient Experience Journal · doi:10.35680/2372-0247.1173 · Cited by 9
Effects of letrozole on serum estradiol and estrone in postmenopausal breast cancer patients and tolerability of treatment: a prospective trial using a highly sensitive LC–MS/MS (liquid chromatography–tandem mass spectrometry) method for estrogen measurement
Faltinová, M., Vehmanen, L., Lyytinen, H. K., Haanpää, M., Hämäläinen, E. K., Tiitinen, A. E., BLOMQVIST, C. P., & Mattson, J. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-07054-3 · Cited by 8
“However, adverse effects of the treatment may negatively impact treatment compliance and Quality of Life (QoL) of the patients [3].”
Background
Exploring the Impact of Sarcopenia on Mortality in Breast Cancer Patients: A Comprehensive Systematic Review and Meta-Analysis
Dai, Y., Lan, J., Li, S., & Xu, G. (2024) · Breast Care · doi:10.1159/000541421 · Cited by 9
“Additionally, the aggressive treatments typically employed in non-metastatic cases, such as surgery and chemotherapy, can result in treatment-related complications, impacting survival rates [46, 47].”
Biomimetic nanoparticles: A revolutionary approach to breast cancer therapy using cell membrane coatings
Chandra, J., Molugulu, N., Gupta, G., Siddiqua, A., Wahab, S., & Kesharwani, P. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.106849 · Cited by 8
Genitourinary syndrome of menopause in breast cancer survivors: Treatments are available
Moreno, A. C., Sikka, S., & Thacker, H. L. (2018) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.85a.17108 · Cited by 8
Including partners in discussions of sexual side effects from breast cancer: a qualitative study of survivors, partners, and providers
Shaffer, K. M., Kennedy, E. M., Glazer, J. V., Clayton, A. H., Cohn, W. F., Reese, J. B., Millard, T. A., Ingersoll, K. S., Ritterband, L. M., & Showalter, S. L. (2022) · Supportive Care in Cancer · doi:10.1007/s00520-022-06917-7 · Cited by 8
“Breast cancer and its treatment can impact every phase of a woman’s sexual response cycle [1, 2], with about three in four breast cancer survivors reporting clinically significant sexual dysfunction [3–5].”
Background
Hormonal Therapy Drug Switching, Out-of-Pocket Costs, and Adherence Among Older Women With Breast Cancer
Qin, X., Huckfeldt, P. J., Abraham, J. M., Yee, D., & Virnig, B. A. (2022) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djac062 · Cited by 8
Validity and reliability of the Patient-Reported Arthralgia Inventory: validation of a newly-developed survey instrument to measure arthralgia
Castel, L. D., Wallston, K. A., Saville, B. R., Alvarez, J., Shields, B. D., Feurer, I. D., & Cella, D. F. (2015) · Patient Related Outcome Measures · doi:10.2147/prom.s47997 · Cited by 8
“The study was approved by the Vanderbilt University institutional review board and consisted of self-administered paper questionnaires completed at weeks 0, 2, 4, 6, 8, 12, and 52.”
Self-citation
Effects of vaginal estrogen on serum estradiol during aromatase inhibitor therapy in breast cancer patients with vulvovaginal atrophy: a prospective trial
Faltinová, M., Vehmanen, L., Lyytinen, H. K., Savolainen-Peltonen, H. M., Virtanen, A., Haanpää, M., Hämäläinen, E. K., Tiitinen, A. E., & Mattson, J. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07564-8 · Cited by 7
“VVA symptoms can also reduce treatment adherence [4], and consequently lead to negative effects on survival [5].”
Leveraging quality by design for the optimization of polycaprolactone/chitosan nanocomposites loaded with tamoxifen for breast cancer therapy
Hammouda, S., Haikal, R. R., Dawood, S., Salakawy, N. E., Abdellatif, A., & Mamdouh, W. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.145226 · Cited by 8
Informing interventions to improve uptake of adjuvant endocrine therapy in women with breast cancer: a theoretical-based examination of modifiable influences on non-adherence
Cahir, C., Bennett, K., Dombrowski, S. U., Kelly, C. M., Wells, M., Watson, E. K., & Sharp, L. (2023) · Supportive Care in Cancer · doi:10.1007/s00520-023-07658-x · Cited by 8
Factors associated with worsening sexual function during adjuvant endocrine therapy in a prospective clinic-based cohort of women with early-stage breast cancer
Verma, N., Blackford, A. L., Thorner, E. D., Lehman, J., Snyder, C. F., Stearns, V., & Smith, K. L. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06750-w · Cited by 8
“Adjuvant endocrine therapies for hormone receptor-positive (HR +) breast cancer, including aromatase inhibitors (AI), tamoxifen, and ovarian function suppression (OFS), have anti-estrogenic effects, often leading to vaginal dryness, dyspareunia, trouble reaching climax, and loss of libido [9].”
Background
First-Generation Asymmetric Synthesis of the Selective Estrogen Receptor Degrader GDC-9545 (Giredestrant) Featuring a Highly Efficient Pictet–Spengler Reaction and a C–N Coupling Reaction
Xu, J. D., Clagg, K., Lim, N., Wuitschik, G., Chung, C. K., Zhang, H., & Gosselin, F. (2021) · Organic Process Research & Development · doi:10.1021/acs.oprd.1c00262 · Cited by 7
Quality of Life in Breast Cancer Patients: An Overview of the Literature
Montazeri, A. (2009) · Springer eBooks · doi:10.1007/978-0-387-78665-0_165 · Cited by 9
Gynecologic Symptoms among Hormone Receptor-Positive Breast Cancer Patients on Oral Endocrine Therapy: A Cross-Sectional Study
Moskalewicz, A., Tomaso, A. D., Kachura, J. J., Scime, S., Nisenbaum, R. A., Lee, R., Haq, R., Derzko, C. M., & Brezden‐Masley, C. (2022) · Current Oncology · doi:10.3390/curroncol29030149 · Cited by 8
“Hot flashes/insomnia was the most frequently reported GS in our study, which is consistent with hot flashes and vasomotor symptoms in general being identified as one of the most commonly reported side effects across both tamoxifen and AI users in clinical trials [4].”
BackgroundInfluential
Quality of Life (QoL) in Postmenopausal Breast Cancer Patients Receiving Adjuvant Hormonal Therapy
Bichoo, R. A., Mishra, A., Lal, P., Chand, G., Agarwal, G., Agarwal, A., & Mishra, S. K. (2021) · Indian Journal of Surgery · doi:10.1007/s12262-021-02766-6 · Cited by 6
Peer Support Physical Activity Interventions Partnering Unknown Survivors of Cancer: A Scoping Review
Smith‐Turchyn, J., Vani, M. F., Murray, R. M., McCowan, M. E., Edward, H., Nayiga, B. K., & Sabiston, C. M. (2023) · Rehabilitation Oncology · doi:10.1097/01.reo.0000000000000343 · Cited by 6
Adjuvant aromatase inhibitors and emerging quality-of-life considerations
Briest, S., & Stearns, V. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.1.1 · Cited by 6
Efficacy of Self-management Programs in Managing Side Effects of Breast Cancer
Boogaard, L., Gater, L., Mori, M., Trincao, A., & Smith‐Turchyn, J. (2016) · Rehabilitation Oncology · doi:10.1097/01.reo.0000475835.78984.41 · Cited by 6

Authors: Cella, D., & Fallowfield, L. J.
Affiliations: Northwestern University (US)
Brighton and Sussex Medical School (GB)
Corresponding author: Cella, David
ORCID: Cella, David
Fallowfield, Lesley J.
Venue: Breast Cancer Research and Treatment
Publisher: Springer Science and Business Media LLC
Published: 2007-09-18
Volume: 107
Issue: 2
Pages: 167-180
ISSN: 0167-6806 (ISSN-L)
1573-7217
DOI: 10.1007/s10549-007-9548-1
OpenAlex: W2034100757
Cited by: 286
References: 83
Citations by year: 2026: 9 · 2025: 17 · 2024: 16 · 2023: 22 · 2022: 20 · 2021: 17 · 2020: 14 · 2019: 16 · 2018: 15 · 2017: 19 · 2016: 17 · 2015: 15 · 2014: 9 · 2013: 14 · 2012: 17
FWCI: 0.88
Type: journal article
Language: en
Open access: green
figshare.com
Licence: cc-by
www.springer.com/tdm (tdm)
Locations: Breast Cancer Research and Treatment (publishedVersion)
PubMed (publishedVersion)
Sussex Research Online (University of Sussex) (submittedVersion)
Figshare (submittedVersion, cc-by)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Health Sciences › Medicine › Oncology › Cancer survivorship and care
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Keywords: breast cancer, adjuvant endocrine therapy, aromatase inhibitors, tamoxifen, treatment-related adverse events, medication adherence, health-related quality of life, vasomotor symptoms, hot flashes, vaginal dryness, dyspareunia, joint pain, adverse event management, hormone receptor-positive breast cancer
MeSH terms: Aromatase, Breast Neoplasms, Clinical Trials as Topic, Endocrine System, Female, Humans, Medical Oncology, Patient Compliance, Quality of Life, Surveys and Questionnaires, Tamoxifen, Treatment Outcome, Chemotherapy, Adjuvant, Antineoplastic Agents, Hormonal, Aromatase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks